Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)

This study is an open-label, parallel, 2-cohort, multicenter, investigator-initiated Phase 2 trial to evaluate the efficacy and safety of binimetinib in patients with advanced or recurrent low-grade glioma or pancreatic cancer harboring BRAF fusion/rearrangement.

Trial Details

NCT ID

NCT06159478

Phase

PHASE2

Sponsor

National Cancer Center, Japan

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

Binimetinib 15 MG

Locations (sample)

Kashiwa, Chiba, Japan|35.86224,139.97732
Sapporo, Hokkaido, Japan|43.06667,141.35
Kyoto, Kyoto, Japan|35.02107,135.75385
Sendai, Miyagi, Japan|38.26667,140.86667
Chuo-ku, Tokyo, Japan

Key Eligibility Criteria

Inclusion criteria for both cohort A and B
BRAF fusion or rearrangement is detected by reimbursed NGS-based cancer gene panel tests, cancer gene panel tests performed under advanced medical …
Unresectable or recurrent
No symptomatic brain metastasis, carcinomatous meningitis or spinal metastasis requiring surgical intervention or radiotherapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →